337 related articles for article (PubMed ID: 32682413)
1. Effect of neoadjuvant therapy on breast cancer biomarker profile.
Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
3. Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.
Tsai YM; Hsu HM; Chen CJ; Hsu KF; Fan HL; Chang H; Chan DC; Yu JC
Ir J Med Sci; 2014 Mar; 183(1):71-5. PubMed ID: 23757214
[TBL] [Abstract][Full Text] [Related]
4. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
6. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
7. Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy.
Ambrosini-Spaltro A; Zunarelli E; Bettelli S; Lupi M; Bernardelli G; Milani M; Ficarra G
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):551-557. PubMed ID: 31335485
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
9. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
[TBL] [Abstract][Full Text] [Related]
14. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
15. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
[TBL] [Abstract][Full Text] [Related]
16. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
[TBL] [Abstract][Full Text] [Related]
17. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
18. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
19. Reliability of receptor assessment on core needle biopsy in breast cancer patients.
Seferina SC; Nap M; van den Berkmortel F; Wals J; Voogd AC; Tjan-Heijnen VC
Tumour Biol; 2013 Apr; 34(2):987-94. PubMed ID: 23269610
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma.
Peng JH; Zhang X; Song JL; Ran L; Luo R; Li HY; Wang YH
Medicine (Baltimore); 2019 Jan; 98(2):e13554. PubMed ID: 30633152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]